Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Theo who wrote (89610)	8/2/2001 11:29:19 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

I like getting as many as I can, I don't read most of them, just check the symbol and the disclaimer.

To: Theo who wrote (89610)	8/2/2001 11:30:50 AM
From: Theo	Respond to of 150070

DNAP - News DNAPrint Awarded "High Tech Corridor" Grant August 02, 2001 07:59:00 AM ET SARASOTA, Fla., Aug. 2 /PRNewswire/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has been awarded a "High Tech Corridor" grant by the University of South Florida (USF) Office of Economic Development. The grant proposal entitled "A Model System for Cancer Pharmacogenomics" was selected for funding under the USF 2001-2002 External Matching Grant program. This program awards grants each year to outstanding companies located in the technology corridor of Florida. The aim of the grant program is to apply USF technology and resources for the promotion of economic growth in the state of Florida. Dr. Hong-Gong Wang from the USF will serve as the principal investigator for the grant and, Hector Gomez, M.D., Ph.D and K. Ponnuswamy, Ph.D. will serve as the leaders for the project on the company side. The grant was written by DNAPrint's Dr. Tony Frudakis. The award provides $305,000 over the next year for the development of an innovative and powerful model system for defining the genetic variance components that underlie variable drug response. The Company intends to use the model system to guide and validate its large-scale population genetics research and product development efforts. If successfully developed and implemented, the model system would impart a significant competitive advantage to DNAPrint within the personalized medicine space. About the Corridor Program: The University of South Florida has established one of its mission priorities as promoting regional economic development. "Economic Development," in a higher education setting, signifies links to the public and private sector for the purposes of encouraging high-technology jobs for graduates, helping raise the standard of living through high-technology partnerships, linking with industry to promote funding and real-world applications for USF's research and academic standing, and in general identifying ways that the university can better meet the needs of the private sector and the region in general. For more information about the Corridor, please visit w3.usf.edu./oed About DNAPrint genomics Inc.: DNAPrint genomics, Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company has a focused effort within the population genomics, informatics, and clinical fields for the application and production of patient-drug classification tests for personalized medicine. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com. All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Contacts: For Scientific inquiries: Tony Frudakis, Ph.D., 941/366-3400 or Other inquiries Tim Wilkins, 941/341-0136 MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com © 2001 PRNewswire